Press Releases

Aurora BioPharma CEO to Present Cutting-Edge Cancer Fighting Technology at BIO-Europe Spring in Stockholm, Sweden

‚Äč

CAMBRIDGE, MA - April 4, 2016 - The CEO of Aurora BioPharma, Inc., Robert Brooks, will present the newest technology based on cutting-edge immunotherapy to kill cancer, at the tenth annual BIO-Europe Spring international life science partnering conference to be held in Stockholm, Sweden, April 4 - 6, 2016. Organized by EBD Group, the event is a world class gathering attracting over 2,000 life science executives. It is co-hosted by Stockholm Business Region and Stockholm Science City Foundation.

Aurora's presentation time slot is as follows:

Event: BIO-Europe Spring

Date: Tuesday, April 5th

Time: 17:30

Room: E 6/7 on level 0

About Aurora BioPharma

Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, Cancer Vaccines, and combinations with Checkpoint Inhibitors. AU105 is a "living-drug" CAR T agent that has shown safety and efficacy in pre-clinical and human clinical trials. A Phase 1 clinical trial was completed in 16 Glioblastoma patients, AU105 met its endpoints of safety, tumor killing efficacy, and showed promising signals of double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in 19 Sarcoma patients was completed, AU-105 met its endpoints of safety, with strong signs of tumor killing efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed a Phase II clinical trial in Small Cell Lung Cancer; and soon to complete a Phase II trial in Breast Cancer with Indoximod, an IDO inhibitor from NewLink Genetics. The Company is planning a combination trial with MX-225 and a PD-1 antibody in lung cancer with a major pharmaceutical company.

About BIO-Europe Spring

BIO-Europe Spring is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking. The event allows delegates to efficiently identify, meet and get partnerships started with life science, from biotech and pharma companies to investors and company executives.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

For media inquiries, please contact:

Candace Cobos

VP, Business Development & Public Relations

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA 02138

Tel: (617) 674-7718 - Fax: (617) 674-7701

Ingraham Building, 25 SE 2nd Avenue, Suite 504

Miami, FL 33131

Tel: (305) 371-2301 - Fax: (305) 371-2304

candace.cobos@aurorabiopharma.net - www.aurorabiopharma.net

New Paradigm in Cancer Immunotherapy

Source: Aurora BioPharma, Inc.